Report Store

The Report Store is a repository of research reports that are available for online purchase. Each provides an in-depth analysis of a single product or class of products in development within the pharmaceutical, biotechnology, device or diagnostics industries. The goal is to provide actionable insights that enable smart investment decisions around emerging product opportunities. Typically, the reports address:

The scientific and medical rationale for use in the target indication
The strength of available human efficacy and safety data, including the probability of late-phase trial success
Regulatory (eg, FDA) concerns and their likely impact on approval and labeling
Commercial opportunities, including an assessment of the competitive landscape and reimbursement issues.

Sort by

Inspire Pharmaceuticals' Denufosol - Clinical, Regulatory and Commercial Risks

This report discusses the clinical, regulatory and commercial challenges for denufosol in cystic fibrosis. Learn More

Ironwood's, Forest Laboratories' and Almirall's Linaclotide

Clinical, regulatory and commercial analysis of linaclotide's prospects in chronic constipation and constipation-predominant irritable bowel syndrome. Learn More

Inhibitex's FV-100 - Will this promising new treatment for shingles live up to its potential?

A discussion of the rationale for FV-100, the early evidence, the factors that could influence the drug's chance for success in phase II, and market considerations that will weigh on Inhibitex and its potential collaborators alike. Learn More

Novartis's Indacaterol - Deciphering FDA’s Complete Response Letter

An analysis of the most probable reasons underlying FDA's Complete Response letter issued to Novartis regarding indacaterol. In addition, a review of LABA class safety, the COPD market and indacaterol's commercial prospects.
Learn More

Neurocrine Biosciences' elagolix - Can Neurocrine replicate Daisy PETAL in phase III?

An analysis of phase II trials, their results and challenges, with potential impact on phase III. A review of elagolix's safety profile and its competitive implications. Learn More

Jazz Pharmaceuticals' Xyrem for Fibromyalgia - Can this notorious drug find redemption in fibromyalgia?

FREE SAMPLE Learn More

NPS' Gattex - Can it slow the flow?

A review of the science, the early results, and regulatory precedents as a means to anticipate Gattex’s chances of success in the ongoing phase III trial and in the marketplace. Learn More

Vertex's VX-770 and VX-809 - Expanding the frontiers of cystic fibrosis treatment

A review of early evidence of drug activity, caveats and interpretation of results. Analysis of market opportunity and upside potential for VX-770 and VX-809. Learn More

Targacept's TC-5214: Neuronal nicotine receptors - a target for depression therapy

Targacept is developing TC-5214 for adjunctive use in major depressive disorder. This report reviews phase II data, likelihood of success in phase III, potential safety concerns, market potential and competition. Learn More

Xoma's Anti-IL1-beta tests the inflammation model of diabetes

The evidence, rationale, competition, market for anti-IL1 beta therapies in type 1 and type 2 diabetes, with a focus on XOMA's 052. Learn More